BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Mometasone/Formoterol: Phase III data

A double-blind, placebo-controlled Phase III trial in 746 patients previously treated with low-dose inhaled corticosteroids with or without a LABA showed that mometasone/formoterol (100 µg/10 µg) twice daily significantly decreased the proportion of patients experiencing severe asthma exacerbations vs. formoterol alone at week 26 (16.5%...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >